Tipelukast

Drug Profile

Tipelukast

Alternative Names: KCA-757; MN-001

Latest Information Update: 26 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kyorin Pharmaceutical
  • Developer MediciNova
  • Class Anti-inflammatories; Antiasthmatics; Small molecules
  • Mechanism of Action 5-lipoxygenase inhibitors; Leukotriene D4 receptor antagonists; Leukotriene receptor antagonists; Phospholipase C inhibitors; Thromboxane A2 receptor antagonists; Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis
  • No development reported Interstitial cystitis
  • Discontinued Asthma

Most Recent Events

  • 24 Jul 2016 MediciNova receives patent allowance for tipelukast in USA
  • 27 Mar 2016 MediciNova receives Notice for Allowance for a patent covering tipelukast in China
  • 23 Mar 2016 MediciNova receives Notice for Allowance for a patent covering tipelukast in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top